The U.S. pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a successful new drug takes, on average, 15 years and more than $1 billion to bring to market. Surrogen offers homozygous gene deletion or homozygous allele introgression in a single generation, which means we can completely knock out both genes in the first generation – the fastest possible method with the most consistent results.
One reason for the high cost and long development cycle is that current animal models are often poor predictors of patient response. They are largely ineffective surrogates. As a result, the only way to determine drug or device efficacy is through human trials, which are slow and expensive to conduct.
Surrogen develops animal models with defined genetic conditions identical to those found in human patients. Our entire platform was developed around the immense value of swine as a genetically, physiologically and anatomically similar model to humans. They are already the standard for preclinical evaluation of endovascular devices.
Surrogen’s pig models accurately model human diseases like heart disease, cancer, diabetes, Alzheimer’s disease, and advance research toward human therapeutics, which will forever change the landscape of preclinical research.
Predictability. Efficiency. Accessibility.
Surrogen’s Patient Models® help improve, enhance and extend human life by providing large animal disease models that faithfully reproduce the disease indications seen in human patients. Leveraging the critical assumption that the best substitutes are those closest to the original; Surrogen’s Patient Models bridge the gap between traditional animal models and clinical studies and serve as a platform to prove or disprove new ideas, exponentially speed up discovery and significantly lower the total cost of getting new medical devices and drugs tested, approved and into use.
Surrogen utilizes game changing genetic technologies to develop large animal models with specific maladies and genetic conditions that provide a groundbreaking, preclinical opportunity for the world’s leading researchers, medical device and pharmaceutical innovators to diminish lead times, lower research costs and reduce failure rates.
Led by a team of experienced geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St. Paul, Minnesota and has offices in Austin, Texas; Campo Grande, Brazil; and Hong Kong.
Wow, does that look like human coronary artery disease. Fantastic work.
~ Medical Device Client
We offer the world’s leading universities, hospitals, researchers, medical device and pharmaceutical companies a safe, reliable and cost-effective model to get new ideas tested and approved for human use.
Our Current Models
Our current disease models include:
- Alzheimer’s Disease (AD)
- Aortic Valve Disease
- Arterial Fibrillation
- Colon Cancer
- Dilated Cardiomyopathy
- Neurofibromatosis (NF1) & Neurofibromatosis 2 (NF2)
- Ovarian Cancer
- Phenylketonuria (PKU)
- Polycystic Kidney Disease (PKD)
Utilizing proprietary gene-editing technologies from Recombinetics, Inc., Surrogen creates large animal models for diabetes, heart disease, atherosclerosis (ATH), cancer, hypertension and neurodegenerative disease. This technology provides assured, consistent replication – faster than all current methods or supply channels. Genetically accurate models provide revolutionary preclinical platforms for accelerated research and therapeutic safety. The result: Superior preclinical safety data and the potential to impact on clinical trial outcomes and costs.
Pioneering methods for precision crossbreeding using gene-editing technologies, Surrogen created the world’s first TALEN-modified livestock, produced more than 1,000 gene-edited animals for research, and produced more than 50 animals in livestock species.
Surrogen utilizes its suite of highly effective gene-editing methods to develop models that faithfully reproduce human disease conditions. The company built its position in animal biotechnology on a strong intellectual property foundation, which includes a global exclusive license to TAL-effector nucleases, a license to clone biomedical swine, and a dozen utility patents covering a breadth of products.